DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
RTA 744 is an investigational drug.
There have been 4 clinical trials for RTA 744. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2007.
The most common disease conditions in clinical trials are Meningitis, Meningeal Carcinomatosis, and Brain Neoplasms. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., M.D. Anderson Cancer Center, and [disabled in preview].
Recent Clinical Trials for RTA 744
|RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases||Reata Pharmaceuticals, Inc.||Phase 2|
|A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis||Reata Pharmaceuticals, Inc.||Phase 1|
|RTA 744 Injection in Patients With Leptomeningeal Disease||Reata Pharmaceuticals, Inc.||Phase 1|